Abstract:Alzheimer's disease (AD), a progressive, degenerative disorder of the brain, is believed to be the most common cause of dementia amongst the elderly. AD is characterized by the presence of amyloid deposits and neurofibrillary tangles in the brain of afflicted individuals. AD is associated with a loss of the presynaptic markers of the cholinergic system in the brain areas related to memory and learning. AD appears to have a heterogeneous etiology with a large percentage termed sporadic AD arising from unknown causes and a smaller fraction of early onset familial AD (FAD) caused by mutations in one of several genes, such as the beta-amyloid precursor protein (APP) and presenilins (PS1, PS2). These proteins along with tau, secretases, such as beta-amyloid cleaving enzyme (BACE), and apolipoprotein E play important roles in the pathology of AD. On therapeutic fronts, there is significant research underway in the development of new inhibitors for BACE, PS-1 and gamma-secretase as targets for treatment of AD. There is also a remarkable advancement in understanding the function of cholinesterase (ChE) in the brain and the use of ChE-inhibitors in AD. A new generation of acetyl- and butyryl cholinesterase inhibitors is being studied and tested in human clinical trials for AD. The development of vaccination strategies, anti-inflammatory agents, cholesterol-lowering agents, anti-oxidants and hormone therapy are examples of new approaches for treating or slowing the progression of AD. In addition, nutritional, genetic and environmental factors highlight more effective preventive strategies for AD. Developments of early diagnostic tools and of quantitative markers are critical to better follow the course of the disease and to evaluate different therapeutic strategies. In this review, we attempt to critically examine recent trends in AD research from molecular, genetic to clinical areas. We discuss various neurobiological mechanisms that provide the basis of new targets for AD drug development. All these current research efforts should lead to a deeper understanding of the pathobiochemical processes that occur in the AD brain in order to effectively diagnose and prevent their occurrence.

Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease

Advancement of Multi-Target Drug Discoveries and Promising Applications in the Field of Alzheimer's Disease.

Development of multiple-target anti-Alzheimer′s agents

Multitargeting the Action of 5-HT6 Serotonin Receptor Ligands by Additional Modulation of Kinases in the Search for a New Therapy for Alzheimer's Disease: Can It Work from a Molecular Point of View?

Serotonin receptors - a potential target for the treatment of Alzheimer’s disease

Mechanistic insights and emerging therapeutic stratagems for Alzheimer's disease

A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease

Innovative pathological network‐based multitarget approaches for Alzheimer's disease treatment

Critical evaluation of current Alzheimer's drug discovery (2018-19) & futuristic Alzheimer drug model approach

A computational model of Alzheimer's disease at the nano, micro, and macroscales

Multi-scale Modeling for Systematically Understanding the Key Roles of Microglia in AD Development

Etiological Insights and Degradation Strategies

Pathogenesis, Animal Models, and Drug Discovery of Alzheimer’s Disease

Current and future therapeutic strategies for Alzheimer's disease: an overview of drug development bottlenecks

Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs

Machine learning in Alzheimer's disease drug discovery and target identification

Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease

Toward a Multiscale Modeling Framework for Understanding Serotonergic Function.

Multiple Targets for the Management of Alzheimer’s Disease

Recent Studies On Mechanisms Of New Drug Candidates For Alzheimer'S Disease Interacting With Amyloid-Beta Protofibrils Using Molecular Dynamics Simulations

Advances In Alzheimer'S Disease: A Multifaceted Review Of Potential Therapies And Diagnostic Techniques For Early Detection